Literature DB >> 10862525

Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol.

D N Li1, A Seidel, M P Pritchard, C R Wolf, T Friedberg.   

Abstract

Most drug metabolizing cytochrome P450s (P450) are predominantly expressed in the liver. In contrast, human CYP1B1 is an extrahepatic P450 which is overexpressed in many tumours and has been strongly implicated in the activation of carcinogens. Rare allelic variants of the CYP1B1 gene which encode an inactive protein have been identified. However, four polymorphisms which most likely do not abolish functionality have been described. In this report, we have characterized the functional consequences of these. A CYP1B1 cDNA, identical to a cDNA published previously, served as a template to introduce allelic changes either separately or in combination. The resulting effects on CYP1B1 activity were determined in membranes isolated from Escherichia coli which coexpressed CYP1B1 together with P450 reductase. None of the allelic changes affected the CYP1B1 expression level. The allelic changes Arg48 to Gly, Ala19 to Ser and Asn453 to Ser had little influence on the Vmax and the Km of the CYP1B1 mediated 2- and 4-hydroxylation of estradiol. In contrast, the Km of these metabolic pathways was increased at least three-fold by the allelic change Va432 to Leu or by simultaneously changing Val432 to Leu and Asn453 to Ser. However, these alterations had little effect on the kinetic parameters of other CYP1B1 mediated reactions such as the epoxidation of (-)-trans-(7R,8R)-benzo[a]pyrene 7,8-dihydrodiol as determined by (r-7,t-8,t-9,c-10)-benzo[a]pyrene tetraol formation, or such as the O-dealkylation of ethoxyresorufin and the 1'-hydroxylation of bufuralol. Molecular modelling suggests that amino acid residue 432 of CYP1B1 may be involved in the interaction between CYP1B1 and P450 reductase. Since 4-hydroxyestradiol has been implicated in hormonal carcinogenesis and CYP1B1 is expressed in target tissues, the data presented demonstrate that polymorphisms in CYP1B1 have the potential to affect disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862525     DOI: 10.1097/00008571-200006000-00008

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  32 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 2.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

3.  Current evidence on the relationship between CYP1B1 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Wenhuan Xu; Yunhai Zhou; Xiaosheng Hang; Di Shen
Journal:  Mol Biol Rep       Date:  2011-06-15       Impact factor: 2.316

4.  Leu/Val SNP polymorphism of CYP1B1 and risk of uterine leiomyoma in a Black population.

Authors:  Virgil S Bideau; Angela T Alleyne
Journal:  Tumour Biol       Date:  2015-10-20

Review 5.  Association of CYP1B1 Leu432Val polymorphism and lung cancer risk: an updated meta-analysis.

Authors:  Xianjun Lao; Xue Qin; Qiliu Peng; Zhiping Chen; Yu Lu; Yanqiong Liu; Shan Li
Journal:  Lung       Date:  2014-07-03       Impact factor: 2.584

6.  CYP1B1 C4326G polymorphism and susceptibility to cervical cancer in Chinese Han women.

Authors:  Ya Li; Shi-Qiao Tan; Qian-Hong Ma; Lei Li; Zhong-Ying Huang; Yan Wang; Shang-Wei Li
Journal:  Tumour Biol       Date:  2013-06-23

Review 7.  Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene.

Authors:  Slobodan P Rendic; Frederick P Guengerich
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

8.  Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

Authors:  Ilaria Pastina; Elisa Giovannetti; Aldo Chioni; Tristan M Sissung; Francesco Crea; Cinzia Orlandini; Douglas K Price; Claudia Cianci; William D Figg; Sergio Ricci; Romano Danesi
Journal:  BMC Cancer       Date:  2010-09-27       Impact factor: 4.430

9.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

10.  Estrogen exposure, metabolism, and enzyme variants in a model for breast cancer risk prediction.

Authors:  Fritz F Parl; Kathleen M Egan; Chun Li; Philip S Crooke
Journal:  Cancer Inform       Date:  2009-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.